Novo Nordisk A/S (NVO), based in Bagsvaerd, Denmark, engages in the R&D, manufacturing, and distribution of pharmaceutical products specializing in treating diabetes, obesity, and rare diseases. The company reported solid results for the second quarter of 2024 and raised its full-year guidance. The company reported net sales of DKK133.41 billion ($19.72 billion), indicating increase of 23.9% year-over-year.
Analysts have high expectations for the company, with a projected 31.1% year-over-year growth in third-quarter revenue, forecasted to reach $10.96 billion, while the company’s EPS for the same quarter is expected to climb by 22.3% year-over-year to $0.87. Moreover, NVO has an impressive earnings surprise history, having topped the consensus revenue and EPS estimates in three of the trailing four quarters.
